Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Imetelstat Study Blip Beats Geron’s Shares Down

Executive Summary

Shares in Geron dropped by nearly 20% to $2.30 on NASDAQ on Sept. 12 following interim clinical data for its lead product, the anticancer imetelstat, from trials conducted by its partner Janssen.

Advertisement

Related Content

Gilead's Late-Stage R&D Misfire Gives Respite To Competing Myelofibrosis Therapies
Stockwatch: Pandora’s Interim Analysis
FDA slaps hold on imetelstat studies; Geron whipped
Geron soars on Mayo Clinic results for imetelstat

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register